Sector News

GSK and Novartis complete deals to reshape both drugmakers

March 2, 2015
Life sciences
(Reuters) – GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers.
 
GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company’s vaccines business and divesting its cancer drugs portfolio to Novartis.
 
The two companies originally announced the transactions in April 2014 to bolster their best businesses and exit weaker ones as the drugs industry contends with healthcare spending cuts and increased generic competition.
 
GSK, which now plans to return 4 billion pounds ($6.2 billion) to shareholders, said it would provide an in-depth view of its prospects at an investor meeting to be held when it reports first-quarter results on May 6.
 
The complex deals are more significant for GSK than for Novartis, reflecting the fact that the British group’s market value is less than half that of its Swiss rival.
 
After holding off from providing financial guidance for this year when it reported annual results last month, GSK said it would provide 2015 earnings guidance and “profile the medium and long-term shape and opportunities” of the group on May 6.
 
The transactions come at a critical time for the British drugmaker, which will see new chairman Philip Hampton take over on May 7.
 
Hampton, who chairs Royal Bank of Scotland, takes the reins following a tough year at GSK, which was hit by a record fine of nearly $500 million in China for bribing doctors and has disappointed investors with weak lung drug sales.
 
The poor performance resulted in the bonus paid to Chief Executive Andrew Witty for 2014 being cut by 51 percent.
 
GSK is receiving net after tax proceeds from the Novartis transactions of $7.8 billion, the majority of which will be distributed to shareholders through a so-called B share scheme.
 
For Novartis, the asset swaps will boost the company’s already substantial presence in oncology and are expected to lift core margins immediately.
 
The Swiss drugmaker now has a portfolio of 22 oncology and haematology medicines, with the GSK deal providing new therapies in melanoma, kidney and blood cancers.
 
Novartis is paying $16 billion for GSK’s cancer drugs, although up to $1.5 billion of this may have to be returned to Novartis if GSK’s melanoma drugs fail to meet expectations. GSK believes the necessary conditions will be satisfied, after recent positive clinical trial results.
 
On top of the transactions with GSK, Novartis also sold its animal health business to Eli Lilly.
 
($1 = 0.6495 pounds) 
 
By Ben Hirschler (Editing by Louise Heavens and Mark Potter)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]